Provided by Tiger Fintech (Singapore) Pte. Ltd.

89Bio, Inc.

7.78
+0.13501.77%
Post-market: 7.850.0750+0.96%18:55 EDT
Volume:1.05M
Turnover:8.15M
Market Cap:1.14B
PE:-2.36
High:7.87
Open:7.79
Low:7.46
Close:7.64
Loading ...

89Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
10 May

89bio Q1 EPS $(0.49) Beats $(0.50) Estimate

Benzinga
·
02 May

BRIEF-89bio Q1 Net Income USD -71.275 Million Vs. IBES Estimate USD -73.6 Million

Reuters
·
02 May

89Bio Reports First Quarter 2025 Financial Results and Corporate Updates

THOMSON REUTERS
·
02 May

89Bio Inc - Phase 3 Entrust Trial Fully Enrolled, Topline Data Expected in 1Q 2026

THOMSON REUTERS
·
02 May

Press Release: 89bio Reports First Quarter 2025 Financial Results and Corporate Updates

Dow Jones
·
02 May

Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket

Benzinga
·
23 Apr

Vaxcyte Stock Plummets 56% in a Month: Here's the Reason

Zacks
·
11 Apr

VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe

Zacks
·
08 Apr

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug

Zacks
·
08 Apr

BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study

Zacks
·
03 Apr

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?

Zacks
·
02 Apr

FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda

Zacks
·
28 Mar

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib

Zacks
·
25 Mar

Elevation Oncology Plunges 42% on Ending Development of Lead Drug

Zacks
·
22 Mar

Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

Zacks
·
22 Mar

Analysts Offer Insights on Healthcare Companies: 89bio (ETNB), Gain Therapeutics (GANX) and Boston Scientific (BSX)

TIPRANKS
·
20 Mar

Goldman Sachs Initiates Coverage on 89bio With Neutral Rating, $11 Price Target

MT Newswires Live
·
14 Mar

89bio Initiated at Neutral by Goldman Sachs

Dow Jones
·
14 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx

Reuters
·
13 Mar